secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0000950170-24-044416
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Inogen EVP R&D & Chief Medical Officer Stanislav Glezer to depart by May 3, 2024
--------------------------------------------------------------------------------

- Mutual separation of Dr. Stanislav Glezer, EVP R&D and Chief Medical Officer, effective on or before May 3, 2024.
- Company expects to enter a separation agreement with benefits consistent with his existing 2021 severance agreement.
- No successor named; disclosure of separation agreement terms to be filed later.
- Glezer was responsible for R&D and clinical strategy; departure leaves a key leadership gap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/0000950170-24-044416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000095017024044416/ingn-20240411.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-044416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer